Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia

European Meeting on HIV & Hepatitis 2018

Acute hepatitis A to E, diagnosis and management - Thomas Berg, MD

European Meeting on HIV & Hepatitis 2018

B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhD

European Meeting on HIV & Hepatitis 2018

Clinical development of ABX464, drug candidate for HIV functional cure- Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018

Reduced drug regimens- Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

What is the place of the monoclonal antibodies in the clinic- Julià Blanco, PhD

European Meeting on HIV & Hepatitis 2018

Comparison of 5 online free access expert databases to check drug-drug interactions between antiretroviral drugs and co-prescribed medications from a French cohort of HIV-infected outpatients - Le

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

Integrating science, logistics and cost in approval of hierarchical testing strategies for NASH - The payer's perspective- Robert LoNigro, MD

International Workshop on NASH Biomarkers 2018

Pathways and priorities for biomarker assessment- Peter Stein, MD

International Workshop on NASH Biomarkers 2018

Repeatability, reproducibility and analytic standards for biomarker development- Abbas Bandukwala

International Workshop on NASH Biomarkers 2018

Linking “intended use” to evidence needed for bringing a biomarker to market- John Sninsky, PhD

International Workshop on NASH Biomarkers 2018

Reporting standards: STARD & TRIPOD- Patrick Bossuyt, PhD

International Workshop on NASH Biomarkers 2018

Quality standards for imaging studies- Claude Sirlin, MD

International Workshop on NASH Biomarkers 2018

Case definitions for use as reference standards- Mohammed Siddiqui, MD

International Workshop on NASH Biomarkers 2018

Defining the reference standard for biomarker development - Histology versus clinical outcomes- Kathleen Donohue, MD

International Workshop on NASH Biomarkers 2018

A Context of Use Framework for Bioanalytical Validation of the CK18 Apoptosis Biomarker for NASH Drug Development- Sumit Kar

International Workshop on NASH Biomarkers 2018

Serum markers of collagen formation are associated with the severity of Liver fibrosis and Non-Alcoholic Steatohepatitis (NASH) histological features and to impaired renal function (IRF) in a NAFLD cohort- Samuel Daniels

International Workshop on NASH Biomarkers 2018

What is needed to link device approval to clinical application approval?- David Litwack, PhD

International Workshop on NASH Biomarkers 2018

Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort- Celine Fournier

International Workshop on NASH Biomarkers 2018

Study design to validate biomarkers of therapeutic response for pre-cirrhotic NASH- Brent Tetri, MD

International Workshop on NASH Biomarkers 2018

Study design to validate biomarkers of therapeutic response in cirrhosis due to NASH- Detlef Schuppan, MD, PhD

International Workshop on NASH Biomarkers 2018

Defining therapeutic response in precirrhotic and cirrhotic NASH- Manal Abdelmalek , MD

International Workshop on NASH Biomarkers 2018

The clinical need for integrated assessment of NASH diabetes and heart disease- Arun Sanyal, MD, MBBS

International Workshop on NASH Biomarkers 2018

Use of plasma PRO-C3, PRO-C5, and PRO-C6 for the diagnosis and follow-up of fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD)- iana Leeming

International Workshop on NASH Biomarkers 2018